Laboratory findings
| Patient no. . | Sample . | MFI (IgG) . | Titer (IgG)* . | MFI (IgM) . | Titer (IgM)* . |
|---|---|---|---|---|---|
| 1 | Posttreatment† | 502 | 160 | 396 | 40 |
| 2 | Pretreatment | 82 | 16 | 0.2 | NT |
| Posttreatment | 68 | NT | −1.1 | ||
| 3 | Pretreatment | 102 | 32 | 14.1 | 2 |
| Posttreatment | 75 | NT | NT | ||
| 4 | Posttreatment | 331 | 640 | 340 | 40 |
| 5 | Posttreatment | 102 | 32 | 5.6 | NT |
| 6 | Posttreatment | 199 | 64 | 5.2 | NT |
| 7 | Posttreatment | 201 | 64 | 3.5 | NT |
| 8 | Posttreatment | 112 | 32 | 20.6 | 4 |
| 9 | Pretreatment | 374 | NT | 16.4 | NT |
| Posttreatment | 106 | 16 | 3.9 | ||
| Negative control | 0.0 ± 1.5 | 0.0 ± 1.4 |
| Patient no. . | Sample . | MFI (IgG) . | Titer (IgG)* . | MFI (IgM) . | Titer (IgM)* . |
|---|---|---|---|---|---|
| 1 | Posttreatment† | 502 | 160 | 396 | 40 |
| 2 | Pretreatment | 82 | 16 | 0.2 | NT |
| Posttreatment | 68 | NT | −1.1 | ||
| 3 | Pretreatment | 102 | 32 | 14.1 | 2 |
| Posttreatment | 75 | NT | NT | ||
| 4 | Posttreatment | 331 | 640 | 340 | 40 |
| 5 | Posttreatment | 102 | 32 | 5.6 | NT |
| 6 | Posttreatment | 199 | 64 | 5.2 | NT |
| 7 | Posttreatment | 201 | 64 | 3.5 | NT |
| 8 | Posttreatment | 112 | 32 | 20.6 | 4 |
| 9 | Pretreatment | 374 | NT | 16.4 | NT |
| Posttreatment | 106 | 16 | 3.9 | ||
| Negative control | 0.0 ± 1.5 | 0.0 ± 1.4 |
MFI indicates MFI obtained with abciximab-coated platelets minus that obtained with uncoated platelets (arbitrary fluorescence units); and NT, not tested.
Reciprocal of the dilution yielding a signal at least twice that obtained with unsensitized platelets.
Posttreatment samples were drawn within 24 hours of the onset of thrombocytopenia.